British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009.
Smith
C H
CH
St John's Institute of Dermatology, King's College London and Guy's and St Thomas' NHS Foundation Trust, London, UK. catherine.smith@kcl.ac.uk
Anstey
A V
AV
Barker
J N W N
JN
Burden
A D
AD
Chalmers
R J G
RJ
Chandler
D A
DA
Finlay
A Y
AY
Griffiths
C E M
CE
Jackson
K
K
McHugh
N J
NJ
McKenna
K E
KE
Reynolds
N J
NJ
Ormerod
A D
AD
D000293:Adolescent; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D001691:Biological Therapy / Q000379:methods; D002648:Child; D002675:Child, Preschool; D003879:Dermatologic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003880:Dermatology / Q000379:methods; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D011247:Pregnancy; D011565:Psoriasis / Q000150:complications / Q000628:therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014777:Virus Diseases / Q000150:complications / Q000188:drug therapy
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D014409:Tumor Necrosis Factor-alpha